- Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor
- Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals
Cambridge, UK, 12 March 2025: 51³Ô¹ÏÍø¹ÙÍø, a biotech company using an AI powered virtual cell to reverse age-driven diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Jill and Laurence will guide 51³Ô¹ÏÍø¹ÙÍø in building a robust product translation and business development strategy respectively, enabling the Company to capitalize on early momentum and progress its pipeline of novel rejuvenation therapeutics towards clinical development.
Following the Company’s recent expansion into